{"id":"W4382198144","doi":"10.1200/jco.22.02887","title":"Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"National Center for Advancing Translational Sciences; Regeneron Pharmaceuticals; National Institutes of Health; Astellas Pharma; G1 Therapeutics; Pharmacyclics; Genentech; UroGen Pharma; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Clovis Oncology; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Seagen; Astellas Pharma US","keywords":"Medicine; Pembrolizumab; Neutropenia; Internal medicine; Rash; Oncology; Urothelial cancer; Adverse effect; Metastatic Urothelial Carcinoma; Cisplatin; Cancer; Nausea; Chemotherapy; Bladder cancer; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001158635,0.0003473574,0.001170895,0.0002051258,0.0002894309,0.000683591,0.0004315918,0.0004778206,0.001667276],"category_scores_gemma":[0.001810068,0.0002663191,0.0006054614,0.0002281797,0.0005735103,0.0005385028,0.0003236598,0.001483723,0.0002498263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007360788,"about_ca_system_score_gemma":0.0009443576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005329243,"about_ca_topic_score_gemma":0.001743313,"domain_scores_codex":[0.999548,0.0002332271,0.00003577127,0.00007566874,0.00004542444,0.00006193113],"domain_scores_gemma":[0.9993989,0.0001674,0.0001680192,0.00005137041,0.0000153735,0.0001988939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7426254,0.01375326,0.01984892,0.0009092992,0.001132291,0.0002852509,0.0003513218,0.002504993,0.02004854,0.0003793243,0.001893695,0.1962678],"study_design_scores_gemma":[0.3393407,0.577242,0.06139535,0.0002532569,0.001351276,0.0008982386,0.0002306208,0.003625402,0.007867139,0.0005661253,0.007176311,0.00005356132],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959215,0.002736439,0.0001272652,0.000183241,0.00004230135,0.0001808542,0.0001144729,0.00001947411,0.0006745241],"genre_scores_gemma":[0.9985233,0.0006220593,0.0002159784,0.0001183426,0.0000245988,0.0001137559,0.000126337,0.000003174937,0.0002524389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001667276,"threshold_uncertainty_score":0.006127536,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09489864755430755,"score_gpt":0.4556505142668498,"score_spread":0.3607518667125422,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}